Evidence map›Paper›PMID 21343701›Full record

ArticleEpigenetics2011

Epigenetic reprogramming as a key contributor to melanocyte malignant transformation.

Fernanda Molognoni, Adriana T Cruz, Fabiana M Meliso, Alice S Morais, Camila F Souza, Patrícia Xander, Jared M Bischof, Fabrício F Costa, Marcelo B Soares, Gangning Liang and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Epigenetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Fernanda MolognoniPharmacology Department, Universidade Federal de São Paulo, São Paulo, Brazil.
Adriana T Cruz
Fabiana M Meliso
Alice S Morais
Camila F Souza
Patrícia Xander
Jared M Bischof
Fabrício F Costa
Marcelo B Soares
Gangning Liang
Peter A Jones
Miriam G Jasiulionis
Universidade Federal de São Paulo · BRNorthwestern Memorial Hospital · USMemorial Medical Center · USSouthern California University for Professional Studies · USUniversity of Southern California · US

Funding

Mechanisms of De Novo Methylation in CancerR37CA082422 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JONES, PETER A · 2009 to 2013
$2.2M
Determining the mechanistic and therapeutic roles of microRNAs in bladder cancerR01CA138794 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIANG, GANGNING · 2010 to 2013
$1.0M
NCI NIH HHS R01 CA138794NCI NIH HHS R37 CA082422
6 · The paper itself

Abstract

Melanoma progression requires deregulation of gene expression by currently uncharacterized epigenetic mechanisms. A mouse model based on changes in cell microenvironment was developed by our group to study melanocyte malignant transformation. Melanoma cell lines (4C11- and 4C11+) were obtained as result of 5 sequential anchorage blockades of non-tumorigenic melan-a melanocytes. Melan-a cells submitted to 4 de-adhesion cycles were also established (4C), are non-tumorigenic and represent an intermediary phase of tumor progression. The aim of this work was to identify factors contributing to epigenetic modifications in early and later phases of malignant transformation induced by anchorage impediment. Epigenetic alterations occur early in tumorigenesis; 4C cell line shows changes in global and gene-specific DNA methylation and histone marks. Many histone modifications differ between melan-a, 4C, 4C11- (non-metastatic melanoma cell line) and 4C11+ (metastatic melanoma cell line) which could be associated with changes in gene and microRNA expression. These epigenetic alterations seem to play a key role in malignant transformation since melanocytes treated with 5-Aza-2'-deoxycytidine before each anchorage blockade do not transform. Some epigenetic changes seem to be also responsible for the maintenance of malignant phenotype, since melanoma cell lines (4C11- and 4C11+) treated in vitro with 5-Aza-2'-deoxycytidine or Trichostatin A showed reduction of tumor growth in vivo. Changes in gene expression reflecting cell adaptation to new environment were also observed. We propose a model in which sustained microenvironmental stress in melanocytes results in epigenetic reprogramming. Thus, after adaptation, cells may acquire epigenetic marks that could contribute to the establishment of a malignant phenotype.

Indexed as

DNA MethylationEpigenesis, GeneticAnimalsCell LineCell Transformation, NeoplasticGene Expression Regulation, NeoplasticHistonesMelanocytesMiceHistones

Identifiers

PMID21343701
PMCPMC3359486
OpenAlexW2062420552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.